Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective

Bibliography

• Barry AR, Koshman SL, Pearson GJ. Adverse drug reactions: The importance of maintaining pharmacovigilance. Can Pharm J (Ott) 2014;147(4):233-8
   Google Scholar
• Ahmad A, Patel I, Balkrishnan R, et al. An evaluation of knowledge, attitude and practice of Indian pharmacists towards adverse drug reaction reporting: A pilot study. Perspect Clin Res 2013;4(4):204-10
   Google Scholar
• Gupta P, Udupa A. Adverse drug reaction reporting and pharmacovigilance: Knowledge, attitudes and perceptions amongst resident doctors. J Pharm Sci Res 2011;3(2):1064-9
   Google Scholar
• Joshi MP, Sugimoto T, Santoso B. Geriatric prescribing in the medical wards of a teaching hospital in Nepal. Pharmacoepidemiol Drug Saf 1997;6(6):417-21
   PubMed Web of Science ®Google Scholar
• Naidu RP. Causality assessment: A brief insight into practices in pharmaceutical industry. Perspect Clin Res 2013;4(4):233-6
   PubMedGoogle Scholar
• Koutkias VG, Jaulent MC. Computational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworks. Drug Saf 2015;38(3):219-32
   PubMed Web of Science ®Google Scholar
• Maigetter K, Pollock AM, Kadam A, et al. Pharmacovigilance in India, Uganda and South Africa with reference to WHO’s minimum requirements. Int J Health Policy Manag 2015;4(5):295-305
   PubMed Web of Science ®Google Scholar
• Pierfitte C, Begaud B, Lagnaoui R, Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol 1999;47(3):329-31
   PubMed Web of Science ®Google Scholar
• Feely J, Moriarty S, O’Connor P. Stimulating reporting of adverse drug reactions by using a fee. BMJ 1990;300(6716):22-3
   PubMed Web of Science ®Google Scholar
• Ghosh AK, De A, Bala NN. Current problems and future aspects of Pharmacovigilance in India. Int J Pharm Bio Sci 2011;2(1):14
   Google Scholar
• Conforti A, Opri S, D’Incau P, et al. Adverse drug reaction reporting by nurses: analysis of Italian pharmacovigilance database. Pharmacoepidemiol Drug Saf 2012;21(6):597-602
   PubMed Web of Science ®Google Scholar
• Misra AK, Thaware P, Sutradhar S, et al. Pharmacovigilance: barriers and challenges mintage. J Pharm Med Sci 2013;2(2):2
   Google Scholar
• Biswas P. Pharmacovigilance in Asia. J Pharmacol Pharmacother 2013;4(Suppl 1):S7-S19
   PubMedGoogle Scholar
• Irawati R. Pharmacovigilance system and its implementation in Indonesia 2013. Available from: http://www.pmda.go.jp/english/events/1st_indonesian-japanese_symposium/5_Bu_Ratna_Revised_12_Feb_13_Presentation_by_Director_of_Distribution_control.pdf [Last accessed 12 January 2015]
   Google Scholar
• National Pharmaceutical Control Bureau. Ministry of Health Malaysia 2015. Available from: http://portal.bpfk.gov.my/newsmaster.cfm?&menuid=27&parentid=16&action=view&retrieveid=125 [Last accessed on 12 January 2015]
   Google Scholar
• Hartigan-Go K. Developing a pharmacovigilance system in the Philippines, a country of diverse culture and strong traditional medicine background. Toxicology 2002;181-182:103-7
   PubMed Web of Science ®Google Scholar
• Wilbur K. Pharmacovigilance in the Middle East. Drug saf 2013;36(1):6
   Web of Science ®Google Scholar
• WHO Programme. Official member countries and years entering the programme [online] 2015. Available from: http://www.who-umc.org/DynPage.aspx?id=100653&mn1=7347&mn2=7252&mn3=7322&mn4=7442 [Last accessed 9 January 2015]
   Google Scholar
• Gonzalez JC, Arango VE, Einarson TR. Contribution of Latin America to pharmacovigilance. Ann Pharmacother 2006;40(7-8):1394-9
   PubMed Web of Science ®Google Scholar
• Hoffmann DE, Fouretier A, Vergne C, Bertram D. Pharmacovigilance regulatory requirements in Latin America. Pharm Med 2012;26(3):12
   Google Scholar
• Vermeer NS, Spierings I, Mantel-Teeuwisse AK, et al. Traceability of biologicals: present challenges in pharmacovigilance. Expert Opin Drug Saf 2015;14(1):63-72
   PubMed Web of Science ®Google Scholar
• Pineda C, Caballero-Uribe CV, de Oliveira MG, et al. Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol 2015;34(4):635-40
   PubMed Web of Science ®Google Scholar
• Tabastajewa J, Rudevich S. Chapter 12: Russian Federation. Available from: http://m.hoganlovells.com/files/Publication/b44feb5c-1129-40c7-a3ae-82594cb3bd27/Presentation/PublicationAttachment/038d5d38-060c-4d00-8d20-86419a2edc05/Tabastajewa_Rudevich.pdf [Last accessed 9 January 2015]
   Google Scholar
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf 2006;29(5):385-96
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 2013;10(7):796-803
   PubMed Web of Science ®Google Scholar
• Soni R, Kesari B. A review on pharmacovigilance. Int J Pharm Sci Rev Res 2014;26(2):237-41
   Google Scholar
• Varallo FR, Guimaraes Sde O, Abjaude SA, Mastroianni Pde C. Causes for the underreporting of adverse drug events by health professionals: a systematic review. Rev Esc Enferm USP 2014;48(4):739-47
   PubMed Web of Science ®Google Scholar
• Safety data exchange agreements (SDEA). Available from: http://www.primevigilance.com/pharmacovigilance-services/pharmacovigilance-system-outsourcing/exchange-agreements-sdea/ [Last accessed 9 January 2015]
   Google Scholar
• Tayade P. Regulations relating to pharmacovigilance in India. Available from: http://archive.expresspharmaonline.com/20110915/fip201108.shtml [Last accessed 31 January 2015]
   Google Scholar
• Schedule Y. Drugs and cosmetics Act. 1945. Available from: http://cdsco.nic.in/html/D&C_Rules_Schedule_Y.pdf [Last accessed on 31 January 2015]
   Google Scholar
• Grootheest AC, Richesson RL. Pharmacovigilance. In: Richesson RL, Andrews JE, editors. Clinical Research Informatics, Health Informatics. Springer-Verlag London Limited, Netherland; 2012
   Google Scholar
• Shibata A, Hauben M. Pharmacovigilance, signal detection and signal intelligence overview. 14th International Conference on Information Fusion Chicago, Illinois, USA, July 5-8. 2011. Available from: http://isif.org/fusion/proceedings/Fusion_2011/data/papers/200.pdf [Last accessed 9 Janury 2015]
   Google Scholar
• CIOMS form I 2013. Available from: http://www.cioms.ch/index.php/cioms-form-i [Last accessed 9 January 2015]
   Google Scholar
• CIOMS 2013. Available from: http://www.cioms.ch/ [Last accessed 9 January 2015]
   Google Scholar
• Macedo AF, Marques FB, Ribeiro CF, Teixeira F. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiol Drug Saf 2005;14(12):885-90
   PubMed Web of Science ®Google Scholar
• Hire RC, Kinage PJ, Gaikwad NN. Causality assessment in pharmacovigilance: A step towards quality care. Sch J App Med Sci 2013;1(5):386-92
   Google Scholar
• Danan G, Benichou C. Causality assessment of adverse reactions to drugs- I. A novel method based on the conclusions of international consensus meetings: application to drug- induced liver injuries. J Clin Epidemiol 1993;46(1):11
   Google Scholar
• Agbabiaka TB, Savovic J, Ernst E. Methods for causality assessment of adverse drug reactions: a systematic review. Drug Saf 2008;31(1):21-37
   PubMed Web of Science ®Google Scholar
• Current Challenges in Pharmacovigilance: Pragmatic Approaches (Report of CIOMS Working Group V). Council for International Organizations of Medical Sciences (CIOMS), 2011
   Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45
   PubMed Web of Science ®Google Scholar
• Rehan HS, Chopra D, Kakkar AK. Physician’s guide to pharmacovigilance: terminology and causality assessment. Eur J Intern Med 2009;20(1):3-8
   PubMed Web of Science ®Google Scholar
• Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. US Food and Drug Administration 2012. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM227351.pdf [Last accessed 1 January 2015]
   Google Scholar
• Guideline on good pharmacovigilance practices (GVP): European Medicines Agency and Heads of Medicines Agencies. Module VI – Management and reporting of adverse reactions to medicinal products (Rev 1). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129135.pdf [Last accessed 7 January 2015]
   Google Scholar
• Rama P, Rodrigues PA, Georgy A. Pharmaovigilance: Perspectives and future challenges in Indian scenario. Asian J Pharm Clin Res 2011;4(4):1-4
   Google Scholar
• Kumar A. Past, present and future of pharmacovigilance in India. Syst Rev Pharm 2011;1(2):55-8
   Google Scholar
• IPC launches medicines adverse effect reporting form for patients. Available from: http://www.pharmabiz.com/NewsDetails.aspx?aid=83575&sid=1 [Last accessed on 31 January 2015]
   Google Scholar
• Pagotto C, Varallo F, Mastroianni P. Impact of educational interventions on adverse drug events reporting. Int J Technol Assess Health Care 2013;29(4):410-17
   PubMed Web of Science ®Google Scholar
• Elkalmi RM, Hassali MA, Ibrahim MI, et al. Community pharmacists’ attitudes, perceptions, and barriers toward adverse drug reaction reporting in Malaysia: a quantitative insight. J Patient Saf 2014;10(2):81-7
   PubMed Web of Science ®Google Scholar
• Rehan HS, Chopra D, Holani SN, Mishra R. An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals. Int J Risk Saf Med 2014;26(1):1-8
   Google Scholar
• Dal Pan GJ. Ongoing challenges in pharmacovigilance. Drug Saf 2014;37(1):1-8
   PubMed Web of Science ®Google Scholar
• Wilbur K. Pharmacovigilance in the Middle East: a survey of 13 arabic-speaking countries. Drug Saf 2013;36(1):25-30
   PubMed Web of Science ®Google Scholar
• Sahu RK, Yadav R, Prasad P, et al. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. SpringerPlus 2014;3:695
   PubMedGoogle Scholar
• Bennett CL, Chen B, Hermanson T, et al. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol 2014;15(13):e594-605
   PubMed Web of Science ®Google Scholar
• Duvvuru Ashok Kumar LR, Shaik Ayub Basha. Pharmacovigilance Programme of India. Available from: http://www.pharmacy.umn.edu/innovations/prod/groups/cop/@pub/@cop/@innov/documents/article/cop_article_496481.pdf [ [Last acessed 19 June 2015]
   Google Scholar
• Adverse event management and reporting systems 2015. Available from: http://www.biotech.com/adverseEventReportSys.php [Last accessed 29 January 2015]
   Google Scholar
• ARISg 2015. Available from: http://arisglobal.com/total-safety/arisg/ [Last accessed 9 January 2015]
   Google Scholar
• Mammi M, Citraro R, Torcasio G, et al. Pharmacovigilance in pharmaceutical companies: An overview. J Pharmacol Pharmacother 2013;4(Suppl 1):S33-7
   Google Scholar
• Lu Z. Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives. Drug Healthc Patient Saf 2009;1:35-45
   Google Scholar